AMGN AMGEN INC
Price Chart
Executive Summary
The Delaware District Court issued a Markman order in a patent case against Amgen, ruling that the claim term 'a functional CH1 domain with an antigen' in the '877 and '179 patents is indefinite, and declining to judicially correct it. This effectively invalidates certain asserted claims, removing a potential liability for Amgen. Other claim terms were construed largely in favor of the plaintiffs, so the case continues on remaining claims.
Court Ruling Details
Actionable Insight
The indefinite finding removes near-term risk from those specific claims, but other claims remain. Monitor for summary judgment motions or settlement developments. Amgen's stock may see a modest positive reaction as a key patent risk is reduced.
Key Facts
- The court found the term 'a functional CH1 domain with an antigen' indefinite, denying judicial correction due to culpability and delay by plaintiffs.
- Other disputed terms (e.g., 'VH binding domain', 'heterologous', 'soluble') were construed in favor of plaintiffs, keeping those claims alive.
- The ruling is interlocutory; the case will proceed to summary judgment or trial on remaining claims.
- No damages or injunctions were awarded; the ruling only affects claim scope and validity.
Financial Impact
Not quantified in the ruling; potential liability reduction from invalidation of certain claims, but overall exposure remains uncertain.
Risk Factors
- Plaintiffs may appeal the indefinite ruling to the Federal Circuit.
- Remaining claims could still lead to infringement findings and damages.
- The court's criticism of plaintiff's conduct may not affect the merits of other claims.
Market Snapshot
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-3hr07p51-AMGN |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
12d ago
|
Court Ruling
| $338.22 $345.46 | ▲ +2.14% | ▲ +1.74% | $355.20 (+5.02%) |
|
May 31, 2026
14d ago
|
ANALYST-DOWNGRADE
| $366.14 $368.86 | ▼ −0.74% | ▼ −0.72% | $355.20 (+2.99%) |
|
May 21, 2026
24d ago
|
ANALYST-UPGRADE
| $344.52 $345.77 | ▲ +0.36% | ▼ −0.66% | $355.20 (+3.10%) |
|
May 19, 2026
26d ago
|
8-K
| $331.63 $337.17 | ▲ +1.67% | ▲ +1.48% | $355.20 (+7.11%) |
|
May 1, 2026
6w ago
|
ANALYST-UPGRADE
| $311.11 $299.36 | ▼ −3.78% | ▼ −4.81% | $355.20 (+14.17%) |
|
Apr 22, 2026
7w ago
|
8-K
| $348.56 $344.53 | ▼ −1.16% | ▼ −1.94% | $355.20 (+1.91%) |
|
Apr 21, 2026
7w ago
|
ANALYST-UPGRADE
| $344.52 $345.77 | ▲ +0.36% | ▼ −0.66% | $355.20 (+3.10%) |
|
Apr 7, 2026
9w ago
|
DEFA14A
| $349.47 $355.35 | ▲ +1.68% | ▲ +1.11% | $355.20 (+1.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access